Praxis Precision Medicines, Inc. Stock Price, News & Analysis

Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on CNS disorders, has granted 6,238 restricted stock units to eight new non-executive employees under its 2024 Inducement Plan. The grants, approved by the Compensation Committee on September 2, 2025, were made in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units will vest over four equal annual installments, contingent upon continued employment. These equity awards are specifically designed for new hires who were not previously Praxis employees, serving as employment inducements.

Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing CNS disorder therapies, has announced an upcoming virtual fireside chat. CEO Marcio Souza will participate in a discussion with TD Cowen's Biotechnology Analyst Ritu Baral on September 2, 2025, at 10:00 AM EST.

The discussion will focus on Praxis' recent presentations at the 36th International Epilepsy Consortium (IEC). The company specializes in developing treatments for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.

Praxis Precision Medicines (NASDAQ: PRAX) will present extensive clinical and preclinical data across its precision epilepsy pipeline at the 36th International Epilepsy Congress (IEC) 2025 in Lisbon from August 30 to September 3.

The company will deliver twelve presentations featuring updates on three key programs: Vormatrigine (RADIANT study topline results in focal onset seizures), Relutrigine (EMBOLD study in SCN2A/SCN8A-DEE and EMERALD study), and Elsunersen (EMBRAVE3 study and emergency use cases).

Presentations will take place across multiple sessions, including platform presentations and poster sessions, with the company maintaining presence at Booth #435.

Praxis Precision Medicines (NASDAQ:PRAX), a clinical-stage biopharmaceutical company focused on CNS disorders, has granted restricted stock unit (RSU) awards to three new non-executive employees. The awards, totaling 3,875 shares of common stock, were issued under the company's 2024 Inducement Plan on August 1, 2025.

The RSUs will vest over four equal annual installments, contingent on continued employment. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement awards for new hires who were not previously Praxis employees.

Praxis Precision Medicines (NASDAQ:PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, has announced its participation in an upcoming virtual fireside chat. CEO Marcio Souza will engage in a discussion with Piper Sandler senior research analyst Yasmin Rahini on August 7, 2025 at 11:00am EST. The company specializes in developing treatments targeting neuronal excitation-inhibition imbalance in CNS disorders.

Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, has announced its upcoming participation in a virtual event. CEO Marcio Souza will engage in a fireside chat hosted by Truist Securities analyst Joon Lee on August 5, 2025 at 10:00 AM EST.

Praxis Precision Medicines (NASDAQ: PRAX) reported significant progress across its epilepsy treatment portfolio in Q2 2025. The company's RADIANT study for vormatrigine showed a 56.3% median reduction in seizure frequency in focal onset seizure patients, with 22% achieving complete seizure elimination. Two registrational studies were initiated: EMERALD for DEEs with relutrigine and EMBRAVE3 for SCN2A GoF with elsunersen.

The FDA granted Breakthrough Therapy Designation for relutrigine in treating SCN2A and SCN8A DEEs. Financially, Praxis maintains a strong position with $446.6 million in cash and investments as of June 30, 2025, extending runway into 2028. Q2 2025 saw a net loss of $71.1 million, with R&D expenses increasing to $63.0 million from $27.3 million year-over-year.

Praxis Precision Medicines (NASDAQ: PRAX) announced positive topline results from its Phase 2 RADIANT study of vormatrigine for focal onset seizures. The study demonstrated a 56.3% median reduction in seizure frequency over 8 weeks, with 22% of patients achieving complete seizure freedom in the final 28 days of treatment.

Key highlights include 54% of patients achieving 50% response in the first week of treatment. Vormatrigine showed a favorable safety profile and demonstrated advantages as a fast-acting, no-titration, once-daily oral drug with no food requirements. The company plans to complete its pivotal POWER1 study in Q4 and initiate POWER2 study based on these results.

Additional data will be presented at the 36th International Epilepsy Congress on August 31, 2025, with plans to present full study results at the American Epilepsy Society Annual Meeting in December 2025.

Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on CNS disorders, has scheduled a significant announcement combining two key updates. The company will release topline results from the RADIANT trial of vormatrigine along with its Q2 2025 financial results before market open on August 4, 2025.

The company will host a live webcast at 8:30 AM ET on the same day to discuss these results. Investors can access the webcast through a registration link or the company's website, with a replay available for 90 days following the event.